Table 2 from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

Summary of toxicities graded as per Common Terminology Criteria for Adverse Events version 4.03 related to vandetanib and/or mTOR inhibitors in three children with newly diagnosed ACVR1-mutant DIPG for a total of 9 cycles of vandetanib and 12 cycles of mTOR-inhibitor (11 cycles of everolimus and 1 cycle of sirolimus)本数据集总结了3例新确诊ACVR1突变型弥漫内生型桥脑胶质瘤（DIPG, Diffuse Intrinsic Pontine Glioma）患儿中，与凡德他尼和/或哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂相关的、按不良事件通用术语标准4.03版（Common Terminology Criteria for Adverse Events version 4.03）分级的毒性反应情况；所有受试者共计接受9个疗程凡德他尼治疗与12个疗程mTOR抑制剂治疗，其中mTOR抑制剂治疗包含11个疗程依维莫司与1个疗程西罗莫司。